A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3-Reference-Cited by-同舟云学术

A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Published:2016-08-19 Issue:1 Volume:5 Page:
ISSN:2193-1801
Container-title:SpringerPlus
language:en
Short-container-title:SpringerPlus

Author:

Foster Graham R.,Chayama Kazuaki,Chuang Wan-Long,Fainboim Hugo,Farkkila Martti,Gadano Adrian,Gaeta Giovanni B.,Hézode Christophe,Inada Yukiko,Heo Jeong,Kumada Hiromitsu,Lu Sheng-Nan,Marcellin Patrick,Moreno Christophe,Roberts Stuart K.,Strasser Simone I.,Thompson Alexander J.,Toyota Joji,Paik Seung Woon,Vierling John M.,Zignego Anna L.,Cohen David,McPhee Fiona,Wind-Rotolo Megan,Srinivasan Subasree,Hruska Matthew,Myler Heather,Portsmouth Simon D.

Funder

Bristol-Myers Squibb (US)

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://link.springer.com/content/pdf/10.1186/s40064-016-2920-z.pdf

Reference29 articles.

1. AASLD/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62(3):932–954

2. Andersen H, Meyer J, Freeman J, Doyle SE, Klucher K, Miller DM et al (2013) Peginterferon lambda-1a, a new therapeutic for hepatitis C infection, from bench to clinic. J Clin Transl Hepatol 1(2):116–124. doi: 10.14218/JCTH.2013.00014

3. Andriulli A, Mangia A, Iacobellis A, Ippolito A, Leandro G, Zeuzem S (2008) Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther 28(4):397–404